PI3K/AKT and MEK/ERK pathways targeted in new therapy for docetaxel-resistant prostate cancer

Germans Trias i Pujol Research InstituteFeb 5 2024

A team of researchers from the Badalona Applied Research Group in Oncology (B·ARGO) and the Urologic Tumours Unit of the Institut Català d'Oncologia (ICO) and the Germans Trias i Pujol Research Institute (IGTP) have found a new therapeutic strategy for patients with a specific subtype of metastatic prostate cancer resistant to standard chemotherapy treatment with docetaxel.

In this study, published in the journal Frontiers in Pharmacology, they propose a new treatment based on a combination of kinase inhibitors in patients who inevitably stop responding to docetaxel. The team found that resistance to this drug is associated with the hyperactivation of the cellular pathways PI3K/AKT and MEK/ERK and have explored the possibility of inhibiting these pathways as a new therapeutic strategy in patients who maintain the function of PTEN, a negative regulatory protein of the PI3K/AKT pathway.

The results of the study have been satisfactory and, for this reason, the team wants to conduct a clinical trial to assess the safety and efficacy of this combination in patients with prostate cancer resistant to docetaxel. Vicenç Ruiz de Porras and Adrià Bernat-Peguera, ICO-IGTP researchers and co-first authors of the study, state that the results of this study "open the door to a new therapeutic strategy for those patients with PTEN wild-type tumors, who have progressed to docetaxel and in whom, unlike PTEN null patients, the efficacy of AKT inhibitors in monotherapy has not been demonstrated."